home / stock / nspr / nspr quote
Last: | $3.4099 |
---|---|
Change Percent: | 2.71% |
Open: | $3.4 |
Close: | $3.32 |
High: | $3.42 |
Low: | $3.244 |
Volume: | 62,830 |
Last Trade Date Time: | 07/30/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.4099 | $3.4 | $3.32 | $3.42 | $3.244 | 62,830 | 07-30-2024 |
$3.32 | $3.36 | $3.32 | $3.4 | $3.25 | 30,625 | 07-29-2024 |
$3.39 | $3 | $3.39 | $3.415 | $2.96 | 106,773 | 07-26-2024 |
$2.98 | $2.95 | $2.98 | $2.98 | $2.8101 | 67,808 | 07-25-2024 |
$2.93 | $2.45 | $2.93 | $2.95 | $2.4005 | 66,156 | 07-24-2024 |
$2.46 | $2.3715 | $2.46 | $2.48 | $2.3715 | 15,238 | 07-23-2024 |
$2.4124 | $2.41 | $2.4124 | $2.4124 | $2.4 | 1,980 | 07-22-2024 |
$2.36 | $2.44 | $2.36 | $2.44 | $2.36 | 4,457 | 07-19-2024 |
$2.4 | $2.38 | $2.4 | $2.4691 | $2.38 | 3,858 | 07-18-2024 |
$2.43 | $2.41 | $2.43 | $2.46 | $2.35 | 16,057 | 07-17-2024 |
$2.44 | $2.43 | $2.44 | $2.5056 | $2.4 | 6,529 | 07-16-2024 |
$2.4427 | $2.44 | $2.4427 | $2.47 | $2.41 | 4,117 | 07-15-2024 |
$2.455 | $2.455 | $2.455 | $2.51 | $2.4127 | 6,862 | 07-12-2024 |
$2.46 | $2.46 | $2.46 | $2.63 | $2.42 | 9,897 | 07-11-2024 |
$2.47 | $2.4 | $2.47 | $2.47 | $2.3802 | 6,806 | 07-10-2024 |
$2.4059 | $2.38 | $2.4059 | $2.4099 | $2.36 | 5,672 | 07-09-2024 |
$2.41 | $2.375 | $2.41 | $2.46 | $2.37 | 11,575 | 07-08-2024 |
$2.39 | $2.3728 | $2.39 | $2.43 | $2.36 | 5,771 | 07-05-2024 |
$2.4399 | $2.34 | $2.4399 | $2.4399 | $2.34 | 2,958 | 07-04-2024 |
$2.4399 | $2.34 | $2.4399 | $2.4399 | $2.34 | 2,958 | 07-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...